Group sequential designs are the most widely used type of adaptive trial in Phase III trials. They differ from a standard fixed term trial by allowing a trial to end early. They use an error spending method which allows a set amount of the total Type I or Type II error at each interim analysis. The ability to end the trial can help reduce costs by getting early approval for highly effective treatments and abandoning trials with poor results.